NCT01932489

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial

THE JULES BORDET INSTITUTE PROGRAM FOR MOLECULAR PROFILING OF METASTATIC LESIONS: FEASIBILITY. PRECISION - Feasibility.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Jules Bordet Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of performing and obtaining data from a few key molecular assays. Patients with metastatic colorectal cancer, non-small cell lung cancer or melanoma will be enrolled. Biopsie from metastatic lesions will be performed. A targeted cancer gene screen assay will be performed using DNA sequencing. Results will be discussed during a molecular screening tumor board.

Conditions

• Colorectal Cancer Metastatic
• Metastatic Melanoma
• Metastatic Non-Small Cell Lung Carcinoma

Interventions

Type	Name	Description
PROCEDURE	Biopsy of a metastatic lesion.

Timeline

• Start date: 2013-12-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2013-08-30
• Last updated: 2018-05-23

Locations

1 site across 1 country: Belgium